PubMed · 14983090
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity.
Abstract
Stimulation of T-cells by IL-2 has been exploited for treatment of metastatic renal carcinoma and melanoma. However, a narrow therapeutic window delimited by negligible stimulation of T-cells at low picomolar concentrations and undesirable stimulation of NK cells at nanomolar concentrations hampers IL-2-based therapies. We hypothesized that increasing the affinity of IL-2 for IL-2Ralpha may create a class of IL-2 mutants with increased biological potency as compared with wild-type IL-2. Towards this end, we have screened libraries of mutated IL-2 displayed on the surface of yeast and isolated mutants with a 15-30-fold improved affinity for the IL-2Ralpha subunit. These mutants do not exhibit appreciably altered bioactivity at 0.5-5 pM in steady-state bioassays, concentrations well below the IL-2Ralpha equilibrium binding constant for both the mutant and wild-type IL-2. A mutant was serendipitously identified that exhibited somewhat improved potency, perhaps via altered endocytic trafficking mechanisms described previously.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Balaji M Rao, Andrew T Girvin, Thomas Ciardelli, Douglas A Lauffenburger, K Dane Wittrup. 2003. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity.. https://doi.org/10.1093/protein%2Fgzg111
Cite the original work for its findings. Save a collection to share your selection of sources.